COVID-19: Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study

• Sponsor: University of Cagliari (Other)
• Overall Status: Completed
• CT.gov ID: NCT04839913
• Collaborator: (none)
• Enrollment: 121
• Location: 1
• Actual Duration (Months): 4.3
• Patients Per Site Per Month: 28.1

Study Details

Study Description

Brief Summary

The investigator analyzed the data of the patients admitted to the surgical department during the period 1St September - 10Th December 2020 to estimate the seroprevalence of SARS-CoV-2 infection in the setting of a non-dedicated COVID-19 hospital and in a mild CoV-2 incidence area and to evaluate the difference of seroprevalence between Spring and Fall seasons in a cohort of patients undergoing surgery.

Condition or Disease	Intervention/Treatment	Phase
SARS-CoV Infection; Seroprevalence; Covid19	Diagnostic Test: Antibodies testing

Study Design

• Study Type: Observational
• Actual Enrollment: 121 participants
• Observational Model: Case-Only
• Time Perspective: Retrospective
• Official Title: Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Update From an Unicentric, Regional Study
• Actual Study Start Date: Sep 1, 2020
• Actual Primary Completion Date: Dec 10, 2020
• Actual Study Completion Date: Jan 10, 2021

Outcome Measures

Primary Outcome Measures

1. SARS-COV-2 seroprevalence [1St September - 10Th December 2020]

   SARS-COV-2 IgG and IgM seroprevalence between spring and fall period

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patient admitted to our unit who had performed SARS-COV-2 serologic test

Exclusion Criteria:

• age < 18

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Cagliari	Cagliari		Italy

Sponsors and Collaborators

• University of Cagliari

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Fabio Medas, Surgical researcher, University of Cagliari
• ClinicalTrials.gov Identifier: NCT04839913
• Other Study ID Numbers: COVID-SER
• First Posted: Apr 9, 2021
• Last Update Posted: Apr 9, 2021
• Last Verified: Apr 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Severe Acute Respiratory Syndrome; Antibodies

Study Results

No Results Posted as of Apr 9, 2021